Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab, Dexamethasone and Lenalidomide in Ultra-Frail Multiple Myeloma
NCT06517017Phase 2Recruiting
- Sponsor
- University of Utah
- Start
- Oct 2025
- Primary completion
- Nov 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), plasma cell leukemia (PCL), sponsored by University of Utah. Started Oct 2025; status: recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT06517017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06517017.